Market Closed -
Nasdaq
01:30:00 27/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.9393
USD
|
-7.00%
|
|
+73.17%
|
+2.94%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
953.2
|
701
|
854.3
|
204.5
|
205.7
|
212.5
|
-
|
-
|
Enterprise Value (EV)
1 |
579.8
|
360.8
|
708.2
|
168.2
|
118.3
|
280
|
339
|
232.3
|
P/E ratio
|
-4.75
x
|
-2.72
x
|
-3.61
x
|
-0.8
x
|
-0.77
x
|
-2.15
x
|
-1.24
x
|
-2.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
2.12
x
|
58.2
x
|
4.4
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
2.8
x
|
92.9
x
|
4.81
x
|
EV / EBITDA
|
-3.13
x
|
-1.55
x
|
-3.3
x
|
-0.78
x
|
-0.65
x
|
-22.6
x
|
-1.99
x
|
-2.22
x
|
EV / FCF
|
-3.92
x
|
-2.03
x
|
-3.72
x
|
-0.9
x
|
-0.74
x
|
24.4
x
|
-3.43
x
|
-16.4
x
|
FCF Yield
|
-25.5%
|
-49.3%
|
-26.9%
|
-111%
|
-135%
|
4.11%
|
-29.1%
|
-6.11%
|
Price to Book
|
2.43
x
|
-
|
-
|
17
x
|
3.28
x
|
-2.43
x
|
-2.18
x
|
-11.2
x
|
Nbr of stocks (in thousands)
|
60,985
|
72,496
|
75,538
|
94,256
|
2,25,409
|
2,26,219
|
-
|
-
|
Reference price
2 |
15.63
|
9.670
|
11.31
|
2.170
|
0.9125
|
0.9393
|
0.9393
|
0.9393
|
Announcement Date
|
24/03/20
|
25/02/21
|
03/03/22
|
17/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
100
|
3.65
|
48.3
|
EBITDA
1 |
-185.2
|
-232.6
|
-214.4
|
-216.8
|
-182.2
|
-12.42
|
-170.3
|
-104.7
|
EBIT
1 |
-186.1
|
-234
|
-216.1
|
-218.6
|
-183.8
|
-93.32
|
-181.3
|
-123.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-93.32%
|
-4,967.67%
|
-255.64%
|
Earnings before Tax (EBT)
1 |
-180.3
|
-243.4
|
-234
|
-229.4
|
-179.8
|
-91.9
|
-180.1
|
-123.1
|
Net income
1 |
-180.3
|
-243.4
|
-234
|
-229.4
|
-179.8
|
-71.74
|
-188
|
-118.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-71.74%
|
-5,151.66%
|
-245.81%
|
EPS
2 |
-3.290
|
-3.550
|
-3.130
|
-2.710
|
-1.180
|
-0.4376
|
-0.7584
|
-0.4467
|
Free Cash Flow
1 |
-147.8
|
-177.9
|
-190.4
|
-187.4
|
-159.2
|
11.5
|
-98.8
|
-14.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
11.5%
|
-2,706.85%
|
-29.4%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/20
|
25/02/21
|
03/03/22
|
17/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
100
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-51.21
|
-53.89
|
-53.41
|
-55.56
|
-53.9
|
-47.48
|
-45.8
|
-40.1
|
-48.74
|
-41.7
|
123.7
|
-36.4
|
-37.5
|
-
|
-
|
EBIT
1 |
-51.66
|
-54.34
|
-53.87
|
-56.02
|
-54.36
|
-47.94
|
-46.3
|
-40.49
|
-49.03
|
-41.96
|
37.21
|
-43.64
|
-44.91
|
-48.18
|
-47.9
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
37.21%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-56.28
|
-57.78
|
-56.47
|
-59.36
|
-55.76
|
-49.16
|
-42.5
|
-40.01
|
-48.15
|
-41.93
|
37.89
|
-43.26
|
-44.43
|
-51.26
|
-52.11
|
Net income
1 |
-56.28
|
-57.78
|
-56.47
|
-59.36
|
-55.76
|
-49.16
|
-42.5
|
-40.01
|
-48.15
|
-41.93
|
61.68
|
-45.15
|
-47.01
|
-51.26
|
-52.11
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
61.68%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7400
|
-0.7600
|
-0.7400
|
-0.6500
|
-0.5900
|
-0.5200
|
-0.4500
|
-0.2100
|
-0.2100
|
-0.1900
|
0.2086
|
-0.1914
|
-0.1957
|
-0.1941
|
-0.1983
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/03/22
|
10/05/22
|
09/08/22
|
03/11/22
|
17/03/23
|
09/05/23
|
08/08/23
|
09/11/23
|
05/03/24
|
07/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
67.6
|
127
|
19.8
|
Net Cash position
1 |
373
|
340
|
146
|
36.4
|
87.4
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-5.44
x
|
-0.7434
x
|
-0.1891
x
|
Free Cash Flow
1 |
-148
|
-178
|
-190
|
-187
|
-159
|
11.5
|
-98.8
|
-14.2
|
ROE (net income / shareholders' equity)
|
-155%
|
-72.3%
|
-106%
|
-344%
|
-480%
|
-481%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-74.5%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
308.1
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
6.440
|
-
|
-
|
0.1300
|
0.2800
|
-0.3900
|
-0.4300
|
-0.0800
|
Cash Flow per Share
|
-2.650
|
-2.570
|
-2.520
|
-2.210
|
-
|
-
|
-
|
-
|
Capex
1 |
2.97
|
1.5
|
1.55
|
0.41
|
-
|
0.5
|
1.89
|
2.12
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
0.5%
|
51.7%
|
4.39%
|
Announcement Date
|
24/03/20
|
25/02/21
|
03/03/22
|
17/03/23
|
05/03/24
|
-
|
-
|
-
|
Last Close Price
0.9393
USD Average target price
6.417
USD Spread / Average Target +583.13% Consensus |
1st Jan change
|
Capi.
|
---|
| +2.94% | 23Cr | | +23.13% | 5.27TCr | | +37.49% | 3.9TCr | | -8.73% | 3.85TCr | | +28.09% | 3.04TCr | | -12.26% | 2.64TCr | | +10.57% | 2.61TCr | | +45.05% | 1.42TCr | | +32.23% | 1.26TCr | | -6.56% | 1.15TCr |
Other Biotechnology & Medical Research
|